Sign In
Buy FBRX
$76.98
+0.450 (+0.588%)
At Close: Jul 30, 2026
Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their Shareholders
08:05pm, Tuesday, 28'th Jul 2026
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of F
Are FBRX, ACA, BGMS Obtaining Fair Deals for their Shareholders?
07:38pm, Monday, 27'th Jul 2026
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Forte Biosciences, Inc. (NASDAQ: FBRX)
02:43pm, Monday, 27'th Jul 2026
NEW YORK, July 27, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and i
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B
12:27pm, Monday, 27'th Jul 2026
Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately
Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover
12:16pm, Monday, 27'th Jul 2026
Global immunology pioneer Argenx SE (NASDAQ:ARGX) on Monday struck a definitive agreement to purchase Forte Biosciences, Inc. (NASDAQ:FBRX) in a substantial all-cash transaction.
Dow Jones still green but Nasdaq slips to start 'massive week' as oil tumbles
10:53am, Monday, 27'th Jul 2026
2:50pm: Market movers Forte Biosciences (NASDAQ:FBRX) shares jumped after argenx agreed to acquire the biotechnology company for approximately $2.2 billion,...
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash.Halper
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash.Halper Sadeh encour
Shareholder Alert: Ademi LLP investigates whether Forte Biosciences, Inc. is obtaining a Fair Price for Public Shareholders
08:57am, Monday, 27'th Jul 2026
MILWAUKEE, July 27, 2026 /PRNewswire/ -- Ademi LLP is investigating Forte (Nasdaq: FBRX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
02:00am, Monday, 27'th Jul 2026
argenx (Euronext and Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have e
Argenx to Buy Forte Biosciences for $2.2 Billion
01:29am, Monday, 27'th Jul 2026
The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
Argenx to buy Forte Biosciences for about $2.2 billion
01:15am, Monday, 27'th Jul 2026
Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
01:07am, Monday, 27'th Jul 2026
AMSTERDAM & DALLAS--(BUSINESS WIRE)--argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have ente
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
01:00am, Monday, 27'th Jul 2026
Transaction builds on argenx's prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in v
